A.DurkinM
Used under license from Lonza, Ltd.
Neurotherapeutics , 17(2), 672683
National Institute of Health (NIH), after analyzing weights and cardiovascular, metabolic risk factors a year after suspending the Wegovy treatment, patients regained two-thirds of the lost weight on average, and their cardiovascular, metabolic risk factors also returned to similar levels to changed weights
In our clinical experience, patients who have been treated for depression or anxiety without adequate response frequently have undiagnosed gut dysbiosis including Candida overgrowth
Because large studies did not show robust, reproducible weightloss outcomes, development as a formal obesity drug was discontinued, and AOD9604 today is typically used offlabel as a wellness or bodycomposition adjunct rather than an FDAapproved obesity medication